Cytokine mediators of septic infections in the normal and granulocytopenic host

European Journal of Haematology

Volumn 50, Issue 5, 1993, Pages 243-249

  Waage, Anders ^a,b   Steinshamn, Sigurd ^a,b  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

cytokine inhibitors; granulocytopenia; interferon gamma; interleukin; septicaemia; tumour necrosis factor

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR;

BACTERIAL INFECTION; HUMAN; MOUSE; NEUTROPENIA; NONHUMAN; RABBIT; REVIEW; SEPTICEMIA;

AGRANULOCYTOSIS; ANIMAL; BLOOD COAGULATION; CELL ADHESION; CELL MOVEMENT; CYTOKINES; FIBRINOLYSIS; HUMAN; SEPTICEMIA; SHOCK, SEPTIC; SUPPORT, NON-U.S. GOV'T;

EID: 0027160946     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.1993.tb00156.x     Document Type: Review

References (63)

1. Shock and tissue injury induced by recombinant human cachectin
2. Acute in vivo effects of human recombinant tumor necrosis factor
3. Tumour necrosis factor in man: clinical and biological observations
4. Anti cachectin/ TNF antibodies prevent septic shock during lethal bacteremia
5. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin
6. Interleukin 1 induces a shock‐like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition
7. Interleukin 1‐induced pathophysiology: Induction of cytokines, development of histopathologic changes, and immunopharmacologic intervention
8. Interleukin 1 receptor antagonist reduces mortality from endotoxin shock
9. A recombinant human receptor antagonist to interleukin 1 improves survival after lethal endotoxemia in mice
10. Interleukin 1 potentiates the lethal effect of tumor necrosis factor α/cachectin in mice
11. Toxicity of tumor necrosis factor is synergistic with gamma‐interferon and can be reduced with cyclooxygenase inhibitors
12. Evidence for IFN‐γ as a mediator of the lethality of endotoxin and tumor necrosis factor‐α
13. Regulation by interferons of the local inflammatory response to bacterial lipopolysaccharide
14. Anti‐interferon‐γ antibody protects mice against the generalized Shwartzman reaction
15. Interferon‐gamma, a mediator of lethal lipopolysaccharide‐induced Shwartzman‐like shock reactions in mice
16. Role of interferon‐γ in experimental gram‐negative sepsis
17. The role of IFN‐γ in the pathology of experimental endotoxemia
18. Cytokine associated tissue injury and lethality in mice: a comparative study
19. Anti‐IL‐6 monoclonal antibodies protect against lethal Escherichia coli infection and lethal tumor necrosis factor‐α challenge in mice
20. Neutrophil activation by recombinant cytokines
21. Cytokine regulation of endothelial cell function
22. Properties of the novel proinflammatory super‐gene “Intercrine” cytokine family
23. Fibrinolytic response to tumor necrosis factor in healthy subjects
24. Activation of coagulation after administration of tumor necrosis factor to normal subjects
25. The immune‐hypothalamic‐pituitary‐adrenal axis
26. Tumor necrosis factor mimics the metabolic response to acute infection in healthy humans
27. The complex pattern of cytokines in serum from patients with meningococcal septic shock
28. Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease
29. Tumor necrosis factor and interleukin‐1 in the serum of children with severe infectious purpura
30. Different role of tumor necrosis factor in septic shock in relation to surgery/polytrauma and meningococcal disease
31. Increased plasma levels of interleukin‐6 in sepsis
32. Dissociation between plasma and monocyte‐associated cytokines during sepsis
33. Prolonged elevation of interleukin‐8 and interleukin‐6 concentrations in plasma and of leukocyte interleukin‐8 mRNA levels during septicemic and localized Pseudomonas peudomallei infection
34. Inter‐leukin‐8 in sepsis: relation to shock and inflammatory mediators
35. Interleukin‐8 in serum and cerebrospinal fluid from patients with meningococcal disease
36. Cachectin/tumor necrosis factor: production, distribution, and metabolic fate in vivo
37. Production and clearance of tumor necrosis factor in rats exposed to endotoxin and dexamethasone
38. Endotoxin, tumor necrosis factor‐α and interleukin 1 induce inter‐leukin 6 production in vivo
39. Experimental endotoxemia in humans: Analysis of cytokine release and coagulation, fibrinolytic, and complement pathways
40. Protection of neutropenic mice from lethal Candida albicans infection by recombinant interleukin 1
41. Pretreatment with recombinant murine tumor necrosis factor alpha/cachectin and murine interleukin 1 alpha protects mice from lethal bacterial infection
42. Local production of tumor necrosis factor alpha, interleukin 1 and interleukin 6 in meningococcal meningitis. Relation to the inflammatory response
43. Compartmentalization of intraalveolar and systemic lipopoly‐saccharide‐induced tumor necrosis factor and the pulmonary inflammatory response
44. Compartmentalization of TNF and IL‐6 in meningitis and septic shock
45. Role of tumor necrosis factor‐alpha in lipopolysaccharide‐induced pathologic alterations
46. Soluble cytokine receptors are present in normal human urine
47. Characterization of a tumor necrosis factor‐α (TNF‐α) inhibitor ‐ evidence for immunological cross‐reactivity with the TNF receptor
48. Characterization in vitro of a human tumor necrosis factor‐binding protein. A soluble form of a tumor necrosis factor receptor
49. Release of soluble receptors for tumor necrosis factor (TNF) in relation to circulating TNF during experimental endotoxinemia
50. Imbalance between tumour necrosis factor‐alpha and soluble TNF receptor concentrations in severe meningococcaemia
51. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor 3 in vitro and in vivo
52. Recombinant soluble tumor necrosis factor receptor proteins protect mice from lipopolysaccharide‐induced lethality
53. Native interleukin 1 inhibitors
54. Interleukin 1 receptor antagonist. A new member of the interleukin 1 family
55. Production of interleukin‐1‐receptor antagonist during experimental endotoxaemia
56. Role of interleukin‐1 in infectious diseases
57. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors
58. Efficacy of a monoclonal antibody directed against tumor necrosis factor in protecting neutropenic rats from lethal infection with Pseudomonas aeruginosa
59. A low dose of recombinant interleukin 1 protects granulocytopenic mice from lethal Gram‐negative infection
60. Prevention of the toxic action of tumor necrosis factor by cyclooxygenase inhibitor and leukopenia
61. Multiple organ damage caused by tumor necrosis factor and prevented by prior neutrophil depletion
62. Tumor necrosis factor and interleukin‐6 in Candida albicans infection in normal and granulocytopenic mice
63. Cytokine and acute‐phase reactant levels in serum of children with cancer admitted for fever and neutropenia